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Abstract
Background: With the arrival of the postgenomic era, there is increasing interest in the discovery of biomarkers for the
accurate diagnosis, prognosis, and early detection of cancer. Blood-borne cancer markers are favored by clinicians, because
blood samples can be obtained and analyzed with relative ease. We have used a combined mining strategy based on an
integrated cancer microarray platform, Oncomine, and the biomarker module of the Ingenuity Pathways Analysis (IPA)
program to identify potential blood-based markers for six common human cancer types.
Methodology/Principal Findings: In the Oncomine platform, the genes overexpressed in cancer tissues relative to their
corresponding normal tissues were filtered by Gene Ontology keywords, with the extracellular environment stipulated and a
corrected Q value (false discovery rate) cut-off implemented. The identified genes were imported to the IPA biomarker
module to separate out those genes encoding putative secreted or cell-surface proteins as blood-borne (blood/serum/
plasma) cancer markers. The filtered potential indicators were ranked and prioritized according to normalized absolute
Student t values. The retrieval of numerous marker genes that are already clinically useful or under active investigation
confirmed the effectiveness of our mining strategy. To identify the biomarkers that are unique for each cancer type, the
upregulated marker genes that are in common between each two tumor types across the six human tumors were also
analyzed by the IPA biomarker comparison function.
Conclusion/Significance: The upregulated marker genes shared among the six cancer types may serve as a molecular tool
to complement histopathologic examination, and the combination of the commonly upregulated and unique biomarkers
may serve as differentiating markers for a specific cancer. This approach will be increasingly useful to discover diagnostic
signatures as the mass of microarray data continues to grow in the ‘omics’ era.
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Introduction
Currently, there is a continued need for the discovery of specific
blood biomarkers to aid in the noninvasive detection of cancer and
the monitoring of the effectiveness of cancer therapy [1–3].
Biomarkers are molecules that are indicators of physiologic state
and hallmarks of change in a tissue or a bodily fluid during a
disease process [3]. Cancer biomarkers in blood are produced by
tumor cells and secreted or released into the bloodstream of
patients [2]. The measurement of biomarkers in blood is a
noninvasive procedure and relatively simple to perform without
requirements for special instruments and personnel.
In pace with the post-genomic era, advanced technologies
including genomic analysis and proteomics have facilitated the
discovery of effective cancer biomarkers [4–7]. One advantage of
high throughput microarray-based genomic analyses is the
capacity to identify a group or cluster of genes overexpressed in
tissue or body fluids that encode putative secreted or cell-surface
proteins [5,6,8]. However, the mining process in microarray-based
analysis typically requires in-depth statistical and analytical skills
and poses a challenge to researchers who do not possess the
required expertise [9]. This paper proposes and presents a
biologist friendly and effective microarray-based mining method
that facilitates such biomarker discovery.
Recently, we described a rapid, systematic mining strategy to
identify overexpressed genes encoding putative hydrolases suitable
for our in-house Enzyme-Mediated Cancer Imaging and Therapy
(EMCIT) technology, an approach that aims to hydrolyze and
precipitate water-soluble, radioactive prodrugs within the extra-
cellular space of solid human tumors for noninvasive diagnosis or
therapy [10–12]. Herein, we apply a mining strategy that enables
the uncovering of potential blood-borne cancer markers in
humans based on the combination of an integrated cancer
microarray platform, Oncomine [13], and the novel biomarker
filtering capability of the Ingenuity Pathways Analysis (IPA) 5.0
program [14]. To identify genes encoding putative secreted or cell-
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3661surface proteins in human blood/serum/plasma as potential
cancer markers, all genes overexpressed in the extracellular
environment of cancerous cells relative to that of corresponding
normal cells were filtered and retrieved from the Oncomine
database and then imported to and analyzed by the biomarker
module of the IPA analysis program. The application of this
mining method has led to the identification of hundreds of
biomarkers in human tumors: prostate (224), breast (176), lung
(244), colon (57), ovary (292), and pancreas (147). The approach
also enabled the ranking and prioritization of the identified
potential marker genes for overexpression according to normalized
absolute Student t values.
It has been observed that the expression of common tumor
markers related to universal oncogenic processes is stable and
unlikely to be affected by the natural progression of cancer [15].
Therefore, the identification of common tumor markers ubiqui-
tously expressed by a few cancer types could increase the
sensitivity and specificity of conventional histopathologic evalua-
tion and could serve the general practice of segregating malignant
from benign conditions independently of individual taxonomies
[16]. Consequently, we determined the biomarkers in common
between each two cancer types. The comparison analysis across six
different human tumors has led to the detection of 20 to 134
biomarkers as common hits between every two cancer types,
suggesting the interrelation of multiple oncogenic pathways. These
identified markers may be used as broad molecular pathology tools
after validation analysis. Finally, given the common biomarkers,
we were able to identify between 3 and 59 potentially unique
biomarkers per cancer type. This is unprecedented since one of the
key drawbacks to current biomarkers is that most of them are not
specific for one cancer type, which can easily lead to false positives
in the early detection of cancer. For instance, serum prostate-
specific antigen (PSA) level for the screening of prostate cancer was
also found to be elevated in patients with breast or lung tumors,
leading to 70% failure of early prostate cancer detection [17,18].
The limited specificity and sensitivity of current early diagnostic
biomarkers has greatly restricted their reliability. Therefore, our
mining method could serve as a general strategy for discovering
more effective individual or grouped specific markers for cancer,
hopefully achieving the clinical objective of screening for early and
specific detection. To our knowledge, this is the first study
examining with an in silico genomic approach upregulated marker
genes unique for one cancer type.
Materials and Methods
The data mining strategy for the discovery of cancer biomarkers
is based on our recently published methodology exploring the
cancer microarray platform, Oncomine, and employing the
advanced knowledge bases of Ingenuity Systems, Ingenuity
Pathways Analysis, to identify extracellular hydrolases in various
types of cancer (unpublished results). Oncomine [13] was chosen
because it is a public cancer microarray platform incorporating
264 independent microarray datasets, totaling more than 18,000
microarray experiments, which span 35 cancer types. It unifies a
large compendium of other published cancer microarray data,
including Gene Expression Omnibus (GEO) [19] and Stanford
Microarray Database (SMD) [20], and uniquely provides
differential expression analyses comparing most major types of
cancer with their respective normal tissues. For example, to
identify potentially important genes in a particular cancer, users
can perform a ‘‘cancer vs. normal’’ analysis for a given cancer type
and those genes that are upregulated in cancer relative to its
normal tissue can be retrieved as a list. Each overexpressed gene in
the list can then be assessed by the Student t test to calculate the P
or Q values (false discovery rate) [21–23], mean expression values
(mean 1, mean 2), and the normalized Student t value. In addition,
Oncomine is integrated with the Gene Ontology (GO) annotations
filter, which allows users to identify genes with certain biological
processes, molecular functions, or cellular locations.
Each of six human tumor types (prostate, breast, lung, colon,
ovary, and pancreas) was used in the ÆÆprofile searchææ function in
the Oncomine database to find the available microarray datasets
related to the specific cancer type. The analysis type ÆÆcancer vs.
normalææ was then applied to filter those microarray datasets
exploring cancer relative to its normal tissue. Next, Gene
Ontology (GO) annotation keywords implicating the extracellular
environment were used to remove those genes unregulated in
cancer. Specifically, upregulated genes associated with the
following GO terms were searched: ÆÆextracellular spaceææ,
ÆÆextracellular regionææ, ÆÆcell surfaceææ, ÆÆplasma membraneææ,
and ÆÆintegral to membraneææ. Each GO annotation term was
conceived and consulted in the GO database [24] to deliver the
largest number of relevant hits which are likely to encode secreted
or cell-surface proteins. Then, a corrected false discovery rate Q-
value threshold (Q#0.05) was used to filter and retrieve those
extracellularly-overexpressed genes with a high confidence of
upregulation. Upregulated genes with a Q value less than 0.05
were only kept in the list for further analysis and filtering
(including the redundant which was removed in the later filtering
step).
Human Genome Organization (HUGO) gene identifiers were
then used to export the gene lists, in the Microsoft Excel format,
into the Ingenuity Pathways Analysis (IPA) program [14], an
application that has been built on a large knowledge database
acquired by manual curation of full texts of peer-reviewed
scientific publications covering information on more than
500,000 mammalian genes or proteins, molecular concepts, and
millions of their pathway interactions. IPA biomarker is a module
within the new Ingenuity Pathways Analysis 5.0 program which
allows the (i) identification and prioritization of the most promising
and relevant biomarker candidates according to characteristics
that make a gene product a biologically plausible biomarker (a
gene or its encoding product has to be linked closely to the
pathology of the disease or is on a pathway that is closely linked to
the effect of a treatment) (ii) determination of whether a particular
gene or protein is detectable in body fluids, and (iii) assessment of
whether the candidate biomarker has a strong association with
disease processes such as cancer. The retrieved overexpressed
genes were imported to the IPA biomarker module, the redundant
was resolved, and those genes encoding plausible markers
associated with cancer were identified. These biomarkers were
further filtered in the IPA biomarker filter module based on the
following criteria: fluid – ÆÆbloodææ or ÆÆplasma/serumææ, disease –
ÆÆcancerææ, species – ÆÆhumanææ. These filtered blood-based
markers were then ranked and prioritized by the abs(t) value,
where t is the normalized Student t test value in Oncomine, to
reflect the quantitative change of expression level between cancer
and its normal tissue, similar to the fold-change value in
microarray experiments. The final set of blood-based markers
was exported and stored in a Microsoft Excel spreadsheet (see
Supplemental file S1) containing the gene product name,
synonyms, abs(t) value, description, HUGO gene symbol,
expression in body fluids, IPA-defined subcellular locations,
disease types, and protein family.
Detailed analysis of resulting protein hits was performed
retrospectively using iHOP (information hyperlinked over pro-
teins) [11,25], a program that finds links and cited articles to
Mining to Identify Biomarkers
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gene name or synonym name is known. Resulting blood-based
markers were checked and consulted by looking up the associated
literature references or original publications. Finally, the accuracy
of the findings was assessed using control cancer markers either
selected as candidate markers by other studies or well known to be
clinically useful.
IPA biomarker comparison is another function within the IPA
biomarker module, which has the capacity to generate a list of
candidate biomarkers common across different diseases [14]. The
program can maximallycomparethe candidatebiomarkers for three
diseases simultaneously. The filtered biomarkers for each of the six
tumor types from the previous step were thus imported and
compared between every two tumor types to determine the common
biomarkers. The retrieved common biomarkers across the six
human tumor types were then used to determine the unique
candidate biomarkers per cancer type by the exclusion method.
Results and Discussion
The general mining strategy for biomarker discovery reported
here is flexible in nature. Researchers may vary the data-filtering
criteria according to their own interests. For example, in the first
step of the mining process (see Figure 1), they might choose to filter
either ‘‘upregulated’’ or ‘‘downregulated’’ genes to identify
markers for diagnosis or they choose to filter ‘‘differentially
expressed’’ genes in various tumor grades or stages to discover
prognostic markers. In the second step, one may choose to filter
eligible biomarkers in different biological fluids (such as saliva,
tears, and urine) and different species (such as mouse and rat).
Moreover, researchers can vary the genomic database and the
pathway analysis program. Although our primary interest is to
identify markers for human cancer, we believe that this mining
strategy can be broadly applied to identify markers for most other
types of diseases.
Identification of eligible cancer markers
Data mining of 4 to 15 microarray datasets from the Oncomine
platform for genes overexpressed in six human cancers compared
with their expression in normal tissues led to the identification of a
list of 3,064 to 19,645 upregulated gene expression profiles per
cancer type. We were mining for upregulated genes because one of
the prevailing hypotheses is that the most promising biomarkers
will be overproduced genes or their protein products [26,27] (this
may not be generally true, and other researchers could choose to
mine downregulated genes for their specific purpose). Ideally,
Figure 1. Scheme for mining overexpressed genes in six human tumors to identify potential blood-borne cancer markers. Microarray
plates at top represent six tissue types searched in Oncomine platform, including prostate, breast, lung, colon, ovary, and pancreas. Step 1:
Overexpressed genes in cancer relative to its corresponding normal tissue were filtered by GO terms and Q value cut-off. Step 2: blood borne markers
were filtered by ÆÆbloodææ, ÆÆserum/plasmaææ, ÆÆcancerææ and ÆÆhumanææ in biomarker module of IPA program. Trapezoid shape in middle represents
biomarker filtering capability of IPA analysis program. Step 3: common markers were determined between every two tumor types. Step 4: unique
markers were identified for each cancer type.
doi:10.1371/journal.pone.0003661.g001
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into the circulatory system during tumorigenesis. They could be
secreted by tumor cells or released consequent to tumor-cell
fragmentation (Figure 2). Therefore, we searched for upregulated
genes by a combination of controlled Gene Ontology keywords to
implicate the extracellular environment (see Materials and Methods)
in cancerous cells including those encoded proteins bound to or
integrated in cell membranes but whose extracellular domains can
be found through shedding in the circulation. When the retrieved
genes were further filtered by the corrected false discovery rate Q
(Q#0.05), between 211 and 2,782 genes per cancer type were
overexpressed in the extracellular environment of cancerous cells
(including the redundant). We used a stringent corrected false
discovery rate cut-off value to select significantly upregulated genes
and to avoid false predictions arising from experimental variation
in different studies. These upregulated genes were imported to the
IPA biomarker analysis module and between 165 and 961 genes
were identified as eligible candidate markers per cancer type
(Table S1).
Identification of blood-borne cancer markers
The eligible markers that we retrieved from IPA biomarker
analysis included those markers upregulated in the tissues or
biological fluids of patients with cancer. Next, we filtered the
blood-borne markers because they have two major advantages
over other types of indicators. First, blood cells communicate with
the cells and extracellular matrixes in almost all tissues and organs
in the body. Thus, the gene expression profiles of blood cells may
reflect the presence of disease in the body [2,3]. Second, blood
sample collection is less invasive and safer, allowing for a larger
sample size and repeated sampling to monitor disease progression.
From the IPA biomarker filter module, between 57 and 292 blood-
borne (blood/plasma/serum) markers were identified per human
cancer type (see identified genes in Supplemental File S1). By
examining IPA and iHOP knowledge bases [11,25], we deter-
mined that the majority of the blood-borne tumor markers are
secreted, or glycosylphosphatidylinositol (GPI)-anchored and
integral membrane proteins. The detection of their upregulation
in patient blood samples can trigger earlier treatment before tumor
growth [2–4]. Further, these upregulated signatures could be
exploited to understand the pathways related to human cancer
and unravel the associations between different tumors. Although
the functional mechanism driving the various gene expression
profiles in the blood of patients with or without cancer is unclear,
the potential clinical utility of these genes or their protein products
is emerging. As controls, we have listed below a few blood-derived
markers, identified by our work, that have also been selected by
other studies as candidate tumor markers or are already being
used clinically,
Erythroblastic leukemia viral oncogene homolog 2
(ErbB2). ErbB2 is commonly referred to as Her-2/neu by
clinicians [28]. It is a cell-membrane-surface-bound tyrosine
kinase receptor that is normally involved in the signal
transduction pathway leading to cell growth and differentiation
[29]. In our study, we identified ErbB2 as a universal blood-borne
biomarker for five cancers (prostate, breast, lung, ovary, and
pancreas). This is consistent with the findings that the
amplification of this gene or overexpression of its protein
product is associated with cancers including breast, lung,
ovarian, and pancreatic [28–31]. In particular, amplification of
ErbB2 gene has been found in 25% to 30% of breast cancer, and it
has been formally approved by the FDA as a serum biomarker for
the diagnosis of breast cancer [30]. To our knowledge, the
overexpression of ErbB2 gene has not been reported for prostate
cancer.
Breast cancer 1/2, early onset (BRCA1/BRCA2). BRCA1
and BRCA2 are genes directly involved in cell growth, division,
and repair of damaged DNA. The variations in either gene or
their protein products have been implicated in prostate, breast,
and ovarian cancers [32]. There is also strong evidence to suggest
that both genes could be used as predictive markers for the
treatment of breast and ovarian cancer [32–35]. We found both
genes as potential markers in these three tumor types as well as
lung cancer. The overexpression of both genes in four human
cancers may suggest that they are involved in a generalized
phenomenon or functional mechanism in patients with these
cancers.
Prostate-specific antigen (PSA). PSA, also known as
kallikrein III (KLK3), is a protein produced by the cells of the
prostate gland and that is often elevated in the presence of prostate
cancer or other prostate disorders [17,18]. It is a well-known
serum biomarker and measurement of serum PSA level is the most
Figure 2. Circulating tumor cells (CTC) and blood-borne markers secreted or released (consequent to tumor-cell fragmentation) in
blood vessel.
doi:10.1371/journal.pone.0003661.g002
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cancer [36]. Consistent with other experimental findings [37], we
identified PSA as a serum marker for a few tumor types including
prostate, breast, and lung cancer, indicating that PSA is not
prostate-cancer-specific.
Hyaluronan-binding protein 2 (HABP2). HABP2 is a
member of the serine protease family that is found in the
plasma/serum and demonstrated to play important roles in cancer
invasion and metastasis [38]. A real-time reverse transcriptase
polymerase chain reaction (RT-PCR) screening study has
demonstrated the specific overexpression of the HABP2 gene in
lung adenocarcinoma, among six candidate marker genes for
detection of non-small cell lung cancer [39]. We identified two of
these six candidate marker genes, HABP2 and CP (ceruloplasmin),
as potential serum marker genes for lung cancer, demonstrating
the usefulness of our mining strategy in determining novel,
potentially useful, clinical blood markers for human cancer.
Insulin-like growth factor-II (IGF-II). IGF-II encodes a
member of the insulin family of polypeptide growth factors that
are implicated in the pathogenesis of neoplasm in various tissues
[40,41]. Interestingly, our mining approach identified IGF-II as a
potential serum marker for breast, lung, and ovarian cancer. It has
been identified by a recent protein microarray experiment based
on a blood test as one of four serum markers for discriminating
between healthy groups and patients with epithelial ovarian cancer
(EOC) [42]. In this proteomic study, IGF-II protein level is
reduced in patients with EOC compared with healthy controls,
whereas in our gene microarray mining it is upregulated in ovarian
cancer. These findings indicate that gene microarray study alone
may be insufficient and a more rigorous study involving
proteomics experiments or antibody microarrays are necessary
to validate the candidate markers at the protein expression level.
Nevertheless, our study is consistent with other findings that the
upregulation of IGF-II level could be used to diagnose breast
[43,44] and lung [45] cancers.
Identification of common tumor biomarkers
The tumor markers shared between each two tumor types
among the six human tumors were analyzed by the biomarker
comparison analysis function of the IPA program and are
summarized in a matrix form (Figure 3; see Supplemental File
S2). Ovarian cancer has the most markers in common with
prostate (113), breast (107), and lung cancer (134) among the 15
different cancer pairs, possibly because we identified ovarian
cancer as having the most blood-borne biomarkers (292) (see
Table S1) among the six cancer types. Nevertheless, these striking
overlaps between different cancer types indicate that the majority
of the candidate marker genes may in fact be closely related to
multiple oncogenic pathways of cancer metastasis. One of the
bottlenecks in discovering appropriate cancer markers is a poor
understanding of the pathophysiology of the disease [26,27,46]. As
such, the universal overexpression of common markers across
different human cancers may help in understanding and
uncovering the generalized functional mechanisms of tumor
growth and invasion. In addition, the commonly upregulated
marker genes may assist in relating the relevant markers to the
pathogenesis of a particular cancer while any correlation with
other cancer types may suggest novel therapeutic targeting
strategies. Moreover, common markers might be useful in
increasing the sensitivity and specificity of conventional evaluation.
For example, the identified universal biomarkers could be used by
pathologists for uncovering cancer invasion when comprehensive
histologic evaluation is insufficient [15]. To test the hypothesis that
common markers shared by various tumor types could be used to
distinguish between benign/malignant conditions, we have
determined the common set of markers across prostate, breast
and lung cancer (see ‘‘Supplemental File S3 – prostate, breast, and
lung common markers.xls’’). Remarkably, after manually consult-
ing the iHOP database and IPA knowledge database, 13 markers
out of the common 35 markers (,1/3) have been literature-
confirmed to serve as prognostic markers for the progression and
Figure 3. Matrix form for the common markers identified for six human tumors in prostate, breast, lung, colon, ovary and pancreas.
a The comparison of biomarkers between the same tissue type is not available.
b The percent overlap of common markers between every two cancer
types is provided in parenthesis.
doi:10.1371/journal.pone.0003661.g003
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direct evidences that the rest of the 22 common markers can
differentiate between benign/malignant conditions, we believe
that they may all be involved in cancer metastasis.
Identification of unique tumor biomarkers
In examining the common biomarkers between each two cancer
types, we observed 3 to 59 biomarkers exclusive to each cancer type
(Table S1, Figure 4; see Supplemental File S2). In effect, less than
twenty percent of the total identified blood-based biomarkers per
cancer type are unique. A few of the biomarkers reported here have
been suggested as putative specific biomarkers by other studies. For
example, leptin (LEP), a protein hormone with important effects in
regulating body metabolism, has been reported as one of the four
specific serum biomarkers for the early detection of ovarian cancer
[42]. Our study confirms its potential as a unique blood-borne
marker for ovarian cancer. Similarly, we identified matrix
metalloproteinase-2 (MMP-2) as a specific biomarker for pancreatic
cancer, consistent with the experimental findings showing that its
upregulation, compared with that of other metalloproteinases, seems
particularly important inthe growth and dissemination of pancreatic
cancer [47–49]. We believe these unique biomarkers could be
combined to produce a panel of markers that could improve
selectivity and sensitivity for the early diagnosis of cancer.
Identification of promising top-ranked marker genes
Another application of our mining strategy is the prioritization
(according to t values) of top-ranked overexpressed marker genes with
biological evidence implicating their significant role in cancer.
Previously little attention has been paid to their potential as candidate
markers or they were missed simply because of the challenge in
validating a large pool of candidate genes. These top-ranked marker
genes are valuable because they are quantitatively more overex-
pressed than the other marker genes and thus increase the sensitivity
of cancer diagnosis. Those scientists interested in discovering cancer
markers could further analyze and validate these candidate markers
to make them clinically useful [26,27]. As examples, we have listed
below four top-ranked genes identified in our study.
Matrix metalloproteinase-1 (MMP-1) for breast
cancer. MMP-1 is a zinc-ion-binding peptidase secreted in the
extracellular space and involved in the breakdown of extracellular
matrix. Upregulation of MMP-1 mRNA and elevated levels of its
protein have been observed in several cancers [50]. However, in
the past, most studies have focused on its diagnostic significance
for lung cancer [51] or its prognostic significance for colorectal
cancer [52]. Notably, our study identified MMP-1 as the most
upregulated marker gene for breast cancer, opening up the
possibility, after follow-up validation studies, for its use as a
putative predictive marker in screening for breast cancer.
CD44 for colorectal cancer. CD44 encodes a cell-surface
glycoprotein involved in cell–cell interactions, cell adhesion, and
migration. This protein participates in a wide variety of cellular
functions, including lymphocyte activation and tumor metastasis
[53]. In the IPA knowledge bases and iHOP database, there is
evidence implicating the expression of this protein in colorectal
cancer [53,54]. We identified CD44 as the most upregulated
marker gene for colon cancer among 57 putative biomarkers.
Thus, CD44 could be another promising diagnostic marker for
screening colorectal cancer.
Ceruloplasmin (CP) for ovarian cancer. CP encodes an
extracellular metalloprotein that binds most of the copper in plasma
and regulates cellular iron-ion homeostasis in the circulation [55]. In
the past, little attention was paid to its role in human neoplasia,
although it had been suspected that the expression of ceruloplasmin
protein is related to ovarian cancer [56]. We identified CP as the
second most upregulated gene for ovarian cancer, indicating its
potential as a promising serum marker.
Notch homolog 4 (NOTCH4) for pancreatic
cancer. NOTCH4 encodes a member of the Notch protein
family that is involved in the Notch signaling network and
presented on the cell surface as a heterodimer. This protein
Figure 4. Potential unique markers identified for each human cancer type. Horizonal axis of plot is tumor type, including prostate, breast,
lung, colon, ovary, and pancreas cancers. Vertical axis on left is number of unique markers identified for each of six cancer types, represented by red
columns in plot. Vertical axis on right is unique marker percentage of total identified blood-borne markers per cancer type, represented by green
columns in plot.
doi:10.1371/journal.pone.0003661.g004
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a role in vascular, renal, and hepatic development [57]. Notch
pathway components and Notch target genes are upregulated in
invasive pancreatic cancer cells [58]. A more detailed gene
expression profiling study has demonstrated that the mRNA of
NOTCH4 is highly upregulated in pancreatic adenocarcinomas
[59]. We identified NOTCH4 as the most specific upregulated
marker gene for pancreatic cancer, strongly suggesting its potential
for the diagnosis of invasive pancreatic cancer.
Conclusion
We present and apply an integrative mining strategy to identify
overexpressed genes which encode secreted proteins as putative
blood-borne biomarkers for six common human tumors. The
mining strategy is based on the combination of a public cancer
microarray platform, Oncomine, and the novel biomarker filtering
capabilities of the IPA pathways analysis program. Our mining
strategy is uniquely biologist friendly and flexible so that it can be
broadly applied to the discovery of biomarkers for many other
disease types. The detection of numerous cancer marker genes that
are clinically useful or experimentally identified supports the
effectiveness of our strategy. We have determined the shared
markers between every two tumor types across the six selected
human tumors; these commonly upregulated marker genes may
serve as a molecular tool to complement conventional blood-assay
examination and distinguish between benign/malignant condi-
tions. The finding that the majority of the identified marker genes
for one cancer type are shared by the other cancer types suggests
the complexity of human cancer and the close relationship of
multiple oncogenic pathways. Finally, we have identified unique
biomarkers for each cancer type. We propose that in combination
they might serve as diffentiating markers for a specific cancer. We
have attempted to identify rapidly by an in-silico approach
significantly upregulated genes as potential blood-borne markers
for human cancers. We hope this study will stimulate further
experimental studies to define clinically useful diagnostic or
prognostic fingerprints in human blood [60]. Nonetheless, this
approach will be increasingly useful to discover putative diagnostic
signatures as the mass of microarray data continues to grow in the
‘omics’ era.
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